GenomeDx Biosciences has partnered with Color to offer Color Test for the genetic testing of patients diagnosed with prostate cancer.

Color Test is a hereditary cancer risk test designed to analyse 30 genes that impact common hereditary cancers such as prostate, breast, ovarian, colorectal, pancreatic, uterine, melanoma and stomach cancers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The purpose of the test is to aid prostate cancer patients in understanding the disease’s hereditary factors and the possibility of development in their family members.

GenomeDx chief executive officer Doug Dolginow said: "The collaboration with Color is consistent with GenomeDx's goal to provide the best genomic and genetic solutions for patients afflicted with prostate cancer. 

"Data from the Color Test will be added to GenomeDx's Decipher GRID research platform, aiding our research activities to discover and develop future cancer solutions."

“Expanding our product offering with this hereditary cancer risk genetic test makes it easier for patients to access information about inherited risk for their families.

See Also:

“Data from the Color Test will be added to GenomeDx's Decipher GRID research platform, aiding our research activities to discover and develop future cancer solutions."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Decipher genomics resource information database (GRID) is a platform for thousands of tumours’ genomic profiles obtained from urological cancer patients.

Color chief executive officer and co-founder Othman Laraki said: "GenomeDx's Decipher tests are an important tool for physicians and patients in the prostate cancer market, and we look forward to partnering with one of the scientific leaders in the field."

By determining the level of risk for certain types of the disease, the Color Test is also intended to help men with a relative diagnosed with hereditary prostate cancer.